Advanced search
Publication Cover
Patient Preference and Adherence Volume 5, 2011 - Issue
Submit an article Journal homepage
93
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Reasons for continuing or discontinuing olanzapine in the treatment of schizophrenia from the perspectives of patients and clinicians

Jian Chen1 Eli Lilly and Company
,
Haya Ascher-Svanum1 Eli Lilly and CompanyCorrespondence[email protected]
,
Allen W Nyhuis1 Eli Lilly and Company
,
Michael G Case1 Eli Lilly and Company
,
Glenn A Phillips1 Eli Lilly and Company
,
Kory J Schuh1 Eli Lilly and Company
&
Vicki Poole Hoffmann2 Lilly USA, LLC, Indianapolis, IN, USA
 show all
Pages 547-554 | Published online: 03 Nov 2011

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

Order Reprints Request Permissions

For more information please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.